The combination of anti‐HER3 (Patritumab) and anti‐MET (PHA665752) drugs was effective against HER3/MET‐high SW1116 cells, indicating the potential of the dual inhibition of HER3 and MET as the possible targeting therapy overcoming the resistance of cancer cells against anti‐HER1 and anti‐HER2 therapy in CRC and various human epithelial cancers. Here, ERBB2 is linked to colorectal carcinoma.